Scholar Rock has announced it has secured $36 million in series B financing.

Scholar Rock, based in Cambridge, Mass., is a biotechnology company focused on developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment. The company’s initial drug discovery programs target specific growth factors which are present in the microenvironments of diseases including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases.

The financing round was led by Fidelity Management and Research Co., with participation from additional new investor Cormorant Asset Management.

All existing investors in Scholar Rock also participated in the financing round, including Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital and The Kraft Group.